Shares of Summit Therapeutics, whose cancer drug candidate turned heads after it outperformed a blockbuster drug from Merck, ...

Mirvetuximab soravtansine was the first ADC to show efficacy as a therapy for platinum-resistant ovarian cancer. Despite high expectations from early-phase studies, the drug initially did not meet the ...

The US FDA has approved Kisqali (ribociclib) for treating early-stage breast cancer in combination with hormone therapy. It ...

Controversial fentanyl lollipops and similar products will no longer be made by drug makers, the U.S. Food and Drug A ...

Researchers have now found a substance that effectively combats glioblastomas, at least in the laboratory: an antidepressant ...

While the new Shield blood test may motivate more people to get screened for colorectal cancer, it also comes with downsides, ...

An NIH-supported clinical trial of pomalidomide in treating hereditary hemorrhagic telangiectasia stopped early due to ...

Elahere, which won initial U.S. Food and Drug Administration approval in 2022 for platinum-resistant ovarian cancer, was the key asset in AbbVie's $10.1 billion acquisition of biotech ImmunoGen that ...

The most common breast cancer is HER2-negative, so called because it has low amounts of one of the proteins that contribute to tumor cell growth, HER2. Despite this common trait, the development of ...

A drug approved for treating the blood cancer multiple myeloma may offer a safe and effective way to reduce the risk of ...

A sub-analysis of the study highlighted that the DermaSensor device effectively detects skin cancer across different skin ...

To date, more than 600 genes are known to cause tumors when their sequences are spoiled by a mutation. Yet there are other ...